Retrophin makes offer for Transcept; investor seeks higher bids
This article was originally published in Scrip
Executive Summary
Retrophin's bid to acquire Transcept Pharmaceuticals may have kicked off a fight over ownership of the Point Richmond, California-based sleep drug developer that now involves Transcept's largest shareholder Roumell Asset Management.